Clinical Development of Urcosimod, a Drug Candidate Targeting CMKLR1 (ChemR23), to Treat Eye Disease & Neuropathic Corneal Pain
Time: 3:30 pm
day: Conference Day Two
Details:
- Spotlighting results from randomized Phase 2b clinical trials of the lipidated peptide urcosimod to treat dry eye disease (DED) and neuropathic corneal disease (NCP)
- Covering in vitro and animal model data on urcosimod, an agonist of the ChemR23 receptor, that led to the decision to develop urcosimod to treat NCP and DED
- Providing advice for those developing drugs
